Human clinical trial data on BPC-157 is limited but growing, and clinical practitioners working with long COVID patients have reported meaningful improvements in fatigue, gut symptoms, and autonomic stability with BPC-157 protocols
The risks : Red light therapy is advertised as a non-invasive therapy
Christopher Centeno of Regenexx has noted, there is no clinical evidence from human trials showing that BPC-157 works for these applications
Platelets are rich in growth factors and other healing compounds, and there is evidence that injecting them into the affected area can help promote healing
Diarrhea The second most common side effect, affecting a higher percentage of participants at higher doses
The key distinction is not stability, but contamination control